Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair

Yanxin Lu, Jakub Kwintkiewicz, Yang Liu, Katherine Tech, Lauren N Frady, Yu-Ting Su, Wendy Bautista, Seog In Moon, Jeffrey MacDonald, Matthew G Ewend, Mark R Gilbert, Chunzhang Yang, Jing Wu, Yanxin Lu, Jakub Kwintkiewicz, Yang Liu, Katherine Tech, Lauren N Frady, Yu-Ting Su, Wendy Bautista, Seog In Moon, Jeffrey MacDonald, Matthew G Ewend, Mark R Gilbert, Chunzhang Yang, Jing Wu

Abstract

Mutations in isocitrate dehydrogenase (IDH) are the most prevalent genetic abnormalities in lower grade gliomas. The presence of these mutations in glioma is prognostic for better clinical outcomes with longer patient survival. In the present study, we found that defects in oxidative metabolism and 2-HG production confer chemosensitization in IDH1-mutated glioma cells. In addition, temozolomide (TMZ) treatment induced greater DNA damage and apoptotic changes in mutant glioma cells. The PARP1-associated DNA repair pathway was extensively compromised in mutant cells due to decreased NAD+ availability. Targeting the PARP DNA repair pathway extensively sensitized IDH1-mutated glioma cells to TMZ. Our findings demonstrate a novel molecular mechanism that defines chemosensitivity in IDH-mutated gliomas. Targeting PARP-associated DNA repair may represent a novel therapeutic strategy for gliomas. Cancer Res; 77(7); 1709-18. ©2017 AACR.

©2017 American Association for Cancer Research.

Figures

Figure 1. IDH1 mutant glioma cells are…
Figure 1. IDH1 mutant glioma cells are sensitive to TMZ
A. TMZ dose-response curves of U87 MG and U251 MG cells with IDH1 mutation for 96 hr (n=3). B. Annexin-V apoptosis analysis of IDH1 mutant cell with TMZ treatment. C. Cell cycle analysis of IDH1 mutant cells with TMZ treatment (left panel). The overview of cell cycle progression with clear G2/M arrest (right panel). D. DNA fragmentation test for IDH1 mutant cells treated with TMZ.
Figure 2. Enhanced DNA damage in IDH1…
Figure 2. Enhanced DNA damage in IDH1 mutant glioma cells
A. Western blotting for γH2A.X expression in IDH1 mutant cells. Protein expression level was determined by densitometry analysis. B. Immunostaining for γH2A.X puncta in IDH1 mutant cells. C. Comet assay demonstrates DNA fragmentation in IDH1 mutant cells. D. Quantitative analysis showed enhancement in DNA fragmentation in IDH1-mutated cells.
Figure 3. Metabolic reprogramming results in chemo-sensitivity…
Figure 3. Metabolic reprogramming results in chemo-sensitivity in IDH1 mutant cells
A. Seahorse XF Cell Mito Stress analysis showed alteration in oxidative metabolism in IDH1 mutant cells (n=4). B. Quantification of baseline oxidative metabolism in IDH1 mutant cells (n=4, **p

Figure 4. Dysfunction of the PARP1 DNA…

Figure 4. Dysfunction of the PARP1 DNA repair pathway in IDH1 mutant cells

A. Immunostaining…

Figure 4. Dysfunction of the PARP1 DNA repair pathway in IDH1 mutant cells
A. Immunostaining of γH2A.X in IDH1 mutant cells treated with TMZ and Ola (Bar=10 µm). B. Quantification of γH2A.X puncta in IDH1 mutant cells treated with TMZ and Ola (n=3, *p

Figure 5. Targeting the PARP DNA repair…

Figure 5. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy

A. Dose-response…

Figure 5. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy
A. Dose-response curves for IDH1 mutant cells treated with TMZ and Ola (n=3). B. Annexin-V apoptosis analysis demonstrated the potentiation effect of Ola for TMZ chemotherapy. C. Quantification of apoptotic cells in IDH1 mutant cells treated with TMZ and/or Ola.

Figure 6. Impaired PARP1 DNA repair defines…

Figure 6. Impaired PARP1 DNA repair defines chemo-sensitivity

Chemotherapy induces damages in chromosomal DNA in…

Figure 6. Impaired PARP1 DNA repair defines chemo-sensitivity
Chemotherapy induces damages in chromosomal DNA in cancer cells. PARP serves an important role in maintaining genomic integrity and counteract with chemo-agent. In tumors with IDH mutation, cells are less capable of maintaining DNA repair mechanism, as deficiency in NAD+ metabolism deprives substrates for the BER pathway. Targeting PARP by olaparib significantly potentiates the therapeutic effect of TMZ in IDH mutant cells.
Similar articles
Cited by
References
    1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73. - PMC - PubMed
    1. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47:458–68. - PubMed
    1. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44. - PMC - PubMed
    1. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30. - PMC - PubMed
    1. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261–5. - PMC - PubMed
Show all 37 references
MeSH terms
[x]
Cite
Copy Download .nbib .nbib
Format: AMA APA MLA NLM
Figure 4. Dysfunction of the PARP1 DNA…
Figure 4. Dysfunction of the PARP1 DNA repair pathway in IDH1 mutant cells
A. Immunostaining of γH2A.X in IDH1 mutant cells treated with TMZ and Ola (Bar=10 µm). B. Quantification of γH2A.X puncta in IDH1 mutant cells treated with TMZ and Ola (n=3, *p

Figure 5. Targeting the PARP DNA repair…

Figure 5. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy

A. Dose-response…

Figure 5. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy
A. Dose-response curves for IDH1 mutant cells treated with TMZ and Ola (n=3). B. Annexin-V apoptosis analysis demonstrated the potentiation effect of Ola for TMZ chemotherapy. C. Quantification of apoptotic cells in IDH1 mutant cells treated with TMZ and/or Ola.

Figure 6. Impaired PARP1 DNA repair defines…

Figure 6. Impaired PARP1 DNA repair defines chemo-sensitivity

Chemotherapy induces damages in chromosomal DNA in…

Figure 6. Impaired PARP1 DNA repair defines chemo-sensitivity
Chemotherapy induces damages in chromosomal DNA in cancer cells. PARP serves an important role in maintaining genomic integrity and counteract with chemo-agent. In tumors with IDH mutation, cells are less capable of maintaining DNA repair mechanism, as deficiency in NAD+ metabolism deprives substrates for the BER pathway. Targeting PARP by olaparib significantly potentiates the therapeutic effect of TMZ in IDH mutant cells.
Figure 5. Targeting the PARP DNA repair…
Figure 5. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy
A. Dose-response curves for IDH1 mutant cells treated with TMZ and Ola (n=3). B. Annexin-V apoptosis analysis demonstrated the potentiation effect of Ola for TMZ chemotherapy. C. Quantification of apoptotic cells in IDH1 mutant cells treated with TMZ and/or Ola.
Figure 6. Impaired PARP1 DNA repair defines…
Figure 6. Impaired PARP1 DNA repair defines chemo-sensitivity
Chemotherapy induces damages in chromosomal DNA in cancer cells. PARP serves an important role in maintaining genomic integrity and counteract with chemo-agent. In tumors with IDH mutation, cells are less capable of maintaining DNA repair mechanism, as deficiency in NAD+ metabolism deprives substrates for the BER pathway. Targeting PARP by olaparib significantly potentiates the therapeutic effect of TMZ in IDH mutant cells.

References

    1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73.
    1. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47:458–68.
    1. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44.
    1. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30.
    1. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261–5.
    1. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio II, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 2012;26:2038–49.
    1. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75:1560–6.
    1. SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012;103:269–73.
    1. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32:783–90.
    1. Minniti G, Scaringi C, Arcella A, Lanzetta G, Di Stefano D, Scarpino S, et al. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. J Neurooncol. 2014;118:377–83.
    1. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.
    1. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.
    1. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.
    1. Ohba S, Mukherjee J, See WL, Pieper RO. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res. 2014;74:4836–44.
    1. Inoue S, Li WY, Tseng A, Beerman I, Elia AJ, Bendall SC, et al. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell. 2016;30:337–48.
    1. Olive PL, Banath JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc. 2006;1:23–9.
    1. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597–604.
    1. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001;61:1957–63.
    1. Borodovsky A, Seltzer MJ, Riggins GJ. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Curr Opin Oncol. 2012;24:83–9.
    1. Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 2014;74:3317–31.
    1. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340:626–30.
    1. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015;28:773–84.
    1. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51:6581–91.
    1. Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci. 1995;20:405–11.
    1. Narahara K, Kimura S, Kikkawa K, Takahashi Y, Wakita Y, Kasai R, et al. Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3. Hum Genet. 1985;71:37–40.
    1. Gabriel JL, Zervos PR, Plaut GW. Activity of purified NAD-specific isocitrate dehydrogenase at modulator and substrate concentrations approximating conditions in mitochondria. Metabolism. 1986;35:661–7.
    1. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, et al. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res. 2015;75:2999–3009.
    1. Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, et al. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc Natl Acad Sci U S A. 2014;111:14217–22.
    1. Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res. 2015;75:4790–802.
    1. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3:709–22.
    1. Cambronne XA, Stewart ML, Kim D, Jones-Brunette AM, Morgan RK, Farrens DL, et al. Biosensor reveals multiple sources for mitochondrial NAD(+) Science. 2016;352:1474–7.
    1. Fouquerel E, Goellner EM, Yu Z, Gagne JP, Barbi de Moura M, Feinstein T, et al. ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion. Cell Rep. 2014;8:1819–31.
    1. Andrabi SA, Umanah GK, Chang C, Stevens DA, Karuppagounder SS, Gagne JP, et al. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci U S A. 2014;111:10209–14.
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
    1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
    1. Bailey ML, O'Neil NJ, van Pel DM, Solomon DA, Waldman T, Hieter P. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. Mol Cancer Ther. 2014;13:724–32.
    1. Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2014;21:258–69.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren